Sangamo Biosciences, Inc. (SGMO) Posts Q2 EPS Loss of $0.20, Releases FY11 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
Financial Fact:
Loss from operations: -19.21M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Loss from operations: -19.21M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.65 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.
Sangamo Biosciences, Inc. sees FY2011 revenue of $10-$12 million, versus the consensus of $11.03 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c; raises guidance
- Bausch + Lomb names Appio interim CEO as Saunders departs
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
